Erratum

Correction: “CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients” by Rae et al [J Natl Cancer Inst (2012) 104 (6): 452-460]. We acknowledged in a Response (1) that retesting for Hardy-Weinberg equilibrium (HWE) suggested deviation from HWE. The sentence in the first paragraph of the Results section of our original report, "The allele frequencies for the seven most common CYP2D6 (ancestral CYP2D6*1, and variants CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, and CYP2D6*41), and UGT2B7 (ancestral UGT2B7*1 and variant UGT2B7*2) alleles were in Hardy–Weinberg equilibrium in this population (Supplementary Table 1, available online)" is incorrect. The correct wording is "Examination of genotypes using the Pearon's χ² test for Hardy-Weinberg equilibrium (HWE) suggest that UGT2B7*2 is in HWE, CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP2D6*41 are not, and there were insufficient number of homozygous variants of CYP2D6*3 and CYP2D6*6 to calculate HWE.” The authors regret this error and would like to note that for CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP2D6*41, in each case there are excesses of homozygotes which can be attributed to the undetected presence of the CYP2D6*5. Patients with unknown heterozygote CYP2D6*5 are misclassified as homozygous genotype for the other allele. Given that CYP2D6*5 is a null allele, undetected CYP2D6*5 does not misclassify poor metabolizers (PM) but only intermediate metabolizers (IM) and extensive metabolizers (EM). In our study all three CYP2D6 phenotypes had very similar outcomes, and therefore, although undetected CYP2D6*5 invalidates HWE, it does not affect the conclusions of our study.